LLY Latest Press Releases

-- April 30, 2026 --

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines PRNewswire 6:45 AM

-- April 27, 2026 --

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera PRNewswire 6:45 AM

-- April 23, 2026 --

The Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial Globe Newswire 6:15 AM

-- April 20, 2026 --

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies PRNewswire 9:11 AM

-- April 16, 2026 --

Lilly confirms date and conference call for first-quarter 2026 financial results announcement PRNewswire 10:00 AM

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health PRNewswire 6:45 AM

-- April 13, 2026 --

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL PRNewswire 6:45 AM

-- April 9, 2026 --

Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. PRNewswire 6:45 AM

-- April 1, 2026 --

FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions PRNewswire 11:33 AM

-- March 31, 2026 --

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Business Wire 10:19 PM

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders PRNewswire 6:45 AM

-- March 28, 2026 --

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity PRNewswire 3:15 PM

-- March 27, 2026 --

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis PRNewswire 9:00 AM

-- March 19, 2026 --

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes PRNewswire 6:45 AM

-- March 16, 2026 --

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

-- March 5, 2026 --

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients PRNewswire 6:00 AM

-- March 3, 2026 --

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight PRNewswire 5:31 PM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 27, 2026 --

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata PRNewswire 8:12 AM

-- February 26, 2026 --

Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight PRNewswire 5:31 PM

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet PRNewswire 6:30 AM

-- February 23, 2026 --

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen PRNewswire 9:00 AM

-- February 19, 2026 --

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Ra, and Others | DelveInsight PRNewswire 5:31 PM

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) PRNewswire 12:15 PM

-- February 18, 2026 --

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight PRNewswire 6:45 AM

-- February 17, 2026 --

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight PRNewswire 5:31 PM

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company Business Wire 8:00 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

Lilly to participate in TD Cowen's 46th Annual Health Care Conference PRNewswire 10:00 AM

USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company PRNewswire 8:00 AM

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer PRNewswire 6:45 AM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 9, 2026 --

Lilly to acquire Orna Therapeutics to advance cell therapies PRNewswire 7:00 AM

-- February 5, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX Business Wire 5:21 PM

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY Business Wire 4:00 PM

-- February 4, 2026 --

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance PRNewswire 6:45 AM

-- January 30, 2026 --

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility PRNewswire 11:00 AM

-- January 23, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX PRNewswire 8:31 PM

-- January 22, 2026 --

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY Business Wire 10:00 AM

-- January 21, 2026 --

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement PRNewswire 10:00 AM

-- January 20, 2026 --

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer PRNewswire 7:45 AM

-- January 9, 2026 --

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets Business Wire 12:58 PM

-- January 8, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX PRNewswire 8:57 PM

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight PRNewswire 2:00 PM

-- January 7, 2026 --

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases PRNewswire 4:18 PM

-- December 18, 2025 --

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial PRNewswire 6:45 AM

-- December 16, 2025 --

Lilly to participate in J.P. Morgan Healthcare Conference PRNewswire 10:00 AM

-- December 12, 2025 --

Updated data for Lilly's Inluriyo (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio (abemaciclib) in ER+, HER2- advanced breast cancer PRNewswire 11:45 AM

-- December 11, 2025 --

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial PRNewswire 6:45 AM

-- December 9, 2025 --

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama PRNewswire 3:30 PM

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition PRNewswire 8:29 AM

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-nave CLL/SLL PRNewswire 7:30 AM

-- December 8, 2025 --

Lilly declares first-quarter 2026 dividend PRNewswire 2:06 PM

Carolyn Bertozzi returns to Lilly board of directors PRNewswire 10:00 AM

-- December 7, 2025 --

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) PRNewswire 4:30 PM

-- December 3, 2025 --

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor PRNewswire 1:00 PM